ArticleFrontiers in microbiology2026
Spermidine protects against ETEC-induced intestinal injury by reshaping the gut microbiota and activating the AhR/IL-22 axis.
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Enterotoxigenic Methods: A mouse model of ETEC K88-induced intestinal injury was established to evaluate the protective effects of SPD. Disease severity, histopathological alterations, inflammatory responses, intestinal permeability, and epithelial barrier integrity were assessed. The protective mechanism of SPD was further investigated using IPEC-J2 cells, pharmacological inhibition of aryl hydrocarbon receptor (AhR), 16S rRNA gene sequencing, and fecal microbiota transplantation (FMT). Results: SPD administration significantly alleviated ETEC-induced intestinal injury in mice, as evidenced by reduced body weight loss, diarrhea severity, histopathological damage, systemic inflammation, and intestinal permeability, together with restoration of tight junction integrity. In ETEC-challenged IPEC-J2 cells, SPD improved cell viability, suppressed pro-inflammatory cytokine production, and restored the expression of AhR, CYP1A1, ZO-1, and occludin. Mechanistically, inhibition of AhR signaling by CH-223191 markedly weakened the protective effects of SPD and reduced CYP1A1 and IL-22 expression. Furthermore, 16S rRNA sequencing revealed that SPD reshaped the gut microbiota, while FMT from SPD-treated donors transferred protective effects to recipient mice. AhR inhibition further attenuated the benefits mediated by microbiota transplantation. Conclusion: These findings demonstrate that SPD protects against ETEC-induced intestinal injury through coordinated regulation of gut microbiota remodeling and activation of the AhR/CYP1A1/IL-22 signaling axis. This study provides mechanistic insights into the role of SPD in maintaining intestinal barrier homeostasis and highlights its potential as a nutritional intervention strategy against enteric bacterial infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.